No Data
BofA Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $68
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $84
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $65
Tarsus Pharmaceuticals Analyst Ratings
Tarsus Pharmaceuticals Price Target Raised to $65 From $63 at Oppenheimer
Express News | Tarsus Pharmaceuticals Inc : BofA Global Research Raises Price Objective to $68 From $62